An insider of the company Ligand Pharmaceuticals Inc, John Higgins also its Chief Executive Officer, disclosed his well-informed sell activities with the U.S. SEC on 21-03-2017. As announced in the document, John had unloaded 4,000 shares of the California-based company. The total insider sale was worth $436,400 USD. At the time of the deal the price of a share was $109.1. This is not his first insider trade, in the last 30 days, he sold another 4,000 shares worth $428,240 USD. Now, he possess 139,171 shares or 0.69% of the company’s total market cap.
Accipiter Capital Management Llc decreased Foresight Energy Lp (FELP) stake by 6.86% reported in 2016Q4 SEC filing. Accipiter Capital Management Llc sold 577,546 shares as Foresight Energy Lp (FELP)’s stock rose 134.57%. The Accipiter Capital Management Llc holds 7.84M shares with $50.70 million value, down from 8.41M last quarter. Foresight Energy Lp now has $767.38 million valuation. The stock increased 0.17% or $0.01 on March 21, reaching $6.03. About shares traded. Foresight Energy LP (NYSE:FELP) has risen 99.67% since August 15, 2016 and is uptrending. It has outperformed by 92.64% the S&P500.
Since November 16, 2016, it had 0 insider purchases, and 5 sales for $7.19 million activity. On Monday, February 27 the insider Aryeh Jason sold $3.40M. FOEHR MATTHEW W sold $711,214 worth of stock or 6,879 shares. The insider HIGGINS JOHN L sold $428,240.
Analysts await Ligand Pharmaceuticals Inc. (NASDAQ:LGND) to report earnings on May, 3. They expect $0.65 EPS, down 15.58% or $0.12 from last year’s $0.77 per share. LGND’s profit will be $12.99 million for 40.02 P/E if the $0.65 EPS becomes a reality. After $-0.15 actual EPS reported by Ligand Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -533.33% EPS growth.
It closed at $104.05 lastly. It is down 8.30% since August 15, 2016 and is downtrending. It has underperformed by 15.33% the S&P500.
Ligand Pharmaceuticals Incorporated is a biopharmaceutical firm that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The company has market cap of $2.08 billion. The Firm employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It currently has negative earnings. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development.
Investors sentiment increased to 1.2 in Q4 2016. Its up 0.12, from 1.08 in 2016Q3. It is positive, as 23 investors sold Ligand Pharmaceuticals Inc. shares while 85 reduced holdings. 39 funds opened positions while 91 raised stakes. 22.77 million shares or 1.00% less from 23.00 million shares in 2016Q3 were reported. Monetary Mngmt Gru Inc reported 100 shares. Tiaa Cref Invest Management reported 60,212 shares. Howe Rusling reported 1,335 shares or 0.03% of all its holdings. Redwood Invs Ltd Liability Company holds 0.59% or 63,765 shares in its portfolio. Illinois-based Envestnet Asset has invested 0% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Nationwide Fund Advisors holds 0.02% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 59,156 shares. The New York-based Morgan Stanley has invested 0% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). First Citizens Financial Bank & Tru Com reported 0.03% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Schwab Charles Investment Mngmt has 0.01% invested in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 86,060 shares. Pnc Fincl Group Inc Inc holds 13,808 shares or 0% of its portfolio. Hap Trading Ltd Limited Liability Company accumulated 11,507 shares or 0.06% of the stock. Nordea Mngmt Ab owns 11,328 shares. Td Asset owns 7,900 shares. Northwestern Mutual Wealth Mngmt reported 0% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Cornerstone Incorporated stated it has 1.28% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND).
Among 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Ligand Pharmaceuticals has $160 highest and $140 lowest target. $150.75’s average target is 44.88% above currents $104.05 stock price. Ligand Pharmaceuticals had 12 analyst reports since September 3, 2015 according to SRatingsIntel. Roth Capital maintained the shares of LGND in report on Wednesday, September 30 with “Buy” rating. The firm earned “Buy” rating on Friday, March 11 by Roth Capital. TH Capital maintained the stock with “Buy” rating in Friday, December 18 report. The company was maintained on Thursday, November 19 by Roth Capital. The rating was maintained by Roth Capital on Monday, September 21 with “Buy”. Roth Capital maintained the stock with “Buy” rating in Thursday, September 3 report. On Wednesday, October 5 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm earned “Overweight” rating on Wednesday, April 13 by Stephens. The firm has “Buy” rating by TH Capital given on Thursday, November 19. TH Capital maintained Ligand Pharmaceuticals Inc. (NASDAQ:LGND) rating on Wednesday, September 30. TH Capital has “Buy” rating and $140 target.
Among 11 analysts covering Foresight Energy LP (NYSE:FELP), 0 have Buy rating, 1 Sell and 10 Hold. Therefore 0 are positive. Foresight Energy LP had 23 analyst reports since July 21, 2015 according to SRatingsIntel. On Friday, September 18 the stock rating was initiated by FBR Capital with “Mkt Perform”. Cowen & Co maintained the shares of FELP in report on Tuesday, November 3 with “Outperform” rating. The firm earned “Neutral” rating on Tuesday, December 8 by Citigroup. The stock of Foresight Energy LP (NYSE:FELP) earned “Mkt Perform” rating by FBR Capital on Thursday, October 13. The firm has “Hold” rating by Stifel Nicolaus given on Friday, October 30. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Friday, January 22. FBR Capital maintained the stock with “Mkt Perform” rating in Thursday, May 12 report. The company was maintained on Wednesday, November 23 by FBR Capital. The firm has “Market Perform” rating by Cowen & Co given on Wednesday, December 9. The firm has “Hold” rating by Deutsche Bank given on Tuesday, November 3.
